The superiority of enzalutamide over placebo was shown with respect to all secondary end points: the proportion of patients with a reduction in the prostate-specific antigen (PSA) level by 50% or more (54% vs. 2%, P
From ph1/2 of enzalutamide, 37% had CTC conversion from favorable to unfavorable.
For JnJs abiraterone ph3, 34-41% had CTC conversion from favorable to unfavorable, while 36-51% had psa decline 50% at week 12.
Based on placebo arm of enzalutamide ph3, it does look like PGNX's anti-PSMA ADC is demonstrating activity. It would be good to see the tables presented in the EORTC conference.